Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership
Crown Bioscience, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005025/en/
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development. (Photo: Business Wire)
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development.
Building on the company’s continued growth, three new roles have been created within the commercial team and will report to Mr. Prosser. Alex Slater, who joined the company last year, has taken on added responsibility for APAC business development as Vice President of Global Business Development; Dr. Jonny McMichael has been appointed to Vice President of Client Experience and Enablement; and Dr. Achim Quandt has joined the company as Executive Director of Product Management.
“Crown Bioscience has grown significantly in recent years, consistently exceeding its annual growth target, and in FY21 we were delighted to record bookings growth of over 40%,” said Armin Spura, CEO. “With these changes announced today and under Michael's continued leadership, we are confident we are putting in place a commercial team that optimally positions Crown Bioscience for our next phase of growth.”
Michael Prosser, CBO, stated: “It’s an honor to be asked to lead the next stage in Crown Bioscience’s commercial growth. Our success to date is directly attributable to our relentless focus on customer experience, product innovation, and setting new industry-leading quality standards, and I’m excited to be working closely with the new team and structure as we strive to continuously improve in all these areas.”
The company added more than four hundred new customers in FY21, and to meet increased customer demand, has accelerated investments in its global footprint, with renovations now complete in APAC laboratories, and notably the formation of a joint venture with sister company MBL in Japan. In Europe and the United States, parallel investments are also planned for site expansions and strategic acquisitions.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005025/en/
Contact information
Crown Bioscience
Louise Stenson
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches Daily Options on the CAC 40® Index2.5.2024 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the availability of Daily Options on the CAC 40® index, further expanding Interactive Brokers’ robust product suite. Daily Options on the CAC 40® index provide experienced investors with another means to execute short-term trading strategies and manage exposure to the French stock market. Milan Galik, Chief Executive Officer of Interactive Brokers, commented on the launch, "We are pleased to offer Daily Options on the CAC 40® index, which will allow our clients to balance risk and swiftly adjust their portfolios in response to market movements. At Interactive Brokers, we strive to equip our clients with an array of products to find global opportunities, and this new offering underscores our commitment to providing traders with comprehensive product solutions.” Daily Options on the CAC 40® index cater to growing demand from institutional and retail investors for options with daily expirations. The
AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity2.5.2024 16:35:00 EEST | Press release
AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502719692/en/ Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher The analysis included 128 diabetes-free adults with obesity who received a lifestyle intervention in addition to being randomized to either a liraglutide (n = 73) or a placebo (n = 55) treatment group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the prima
Brightcove Integrates New AWS-Powered Generative AI Solution to Enhance Its Award-Winning Customer Service2.5.2024 16:00:00 EEST | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today shared it has implemented Amazon Q Business, a new generative AI assistant on Amazon Web Services (AWS). Using its own public documentation, product, and release notes, Brightcove is leveraging the new assistant internally for real-world use cases applicable to the media and entertainment technology sector. Brightcove is tapping into the technology to build a program to equip its global services and customer success team to further bolster its award-winning customer service. As an early adopter of Amazon Q, Brightcove has launched the “Brightcove Expert Bot,” an AI-powered chatbot embedded into the internal tools, as a new resource for the customer and product support teams. Streamlining its customer support processes enables employees to quickly and effectively find relevant information, solve technical cases, analyze support requests, summarize support tickets, and use those results to help recomm
Power2Drive Europe: Contributing to the Energy Transition With Bidirectional Charging2.5.2024 15:39:00 EEST | Press release
E-mobility is about much more than driving on climate-neutral electricity from renewable sources. The batteries of electric vehicles can be used as temporary storage. And it’s not just vehicle owners who benefit from this: In the medium-term, bidirectional charging can take the burden off distribution grids while making them more flexible. Power2Drive Europe, the international exhibition for charging infrastructure and e-mobility, showcases the latest state of the art. As part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, it will take place from June 19–21, 2024, at Messe München. The Power2Drive Europe Conference, the industry's meeting point and forum for exchange and discourse among experts, stakeholders, and thought leaders in the new mobility sector, kicks off one day earlier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502196803/en/ Power2Drive Europe 2024 highl
Owlet Announces European Medical Certification of Dream SockⓇ2.5.2024 15:37:00 EEST | Press release
Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, announces the EU medical device certification of Dream Sock. This EU-CE-Mark certification, issued by Owlet’s EU notified body, signifies that Owlet’s Dream Sock has been assessed and certified to meet safety and health requirements set out under EU medical device legislation. With this certification, Owlet plans to expand its medical-device product portfolio to even more caregivers around the world. This EU medical device certification follows two marketing authorizations from the U.S. Food and Drug Administration (the “FDA”), for Dream Sock, with new medical technology for healthy infants over-the-counter without a prescription, and for BabySat Ⓡ, a prescription-only pulse oximeter designed for use with babies that have a pre-existing medical condition. “Our mission to be there for every parent and every baby becomes even more realized with the European medical certification for Dream Sock,” s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom